Biden proposed Tuesday to give millions more Americans access to weight loss drugs – but Trump's incoming health chief looked ...

The Biden administration wants to expand coverage of anti-obesity medications to millions on Medicare, Medicaid.

About 42% of U.S. adults are obese, the CDC says. GLP-1 medications have changed the picture for people hoping to reduce risks with obesity.

Amgen Inc. announced on Tuesday that its experimental weight-loss drug, MariTide, demonstrated an average weight reduction of ...

Popular weight-loss drugs like Wegovy or Ozempic would be covered by Medicare or Medicaid under a newly-proposed rule by the ...

Millions of Americans with obesity would be eligible to have popular weight-loss drugs like Wegovy or Zepbound covered by Medicare or Medicaid under a new rule the Joe Biden administration proposed ...

About 7.4 million obese Americans could have insurance coverage for drugs like Ozempic and Wegovy if the Trump administration ...

Amgen also tested MariTide in a population with Type 2 diabetes, a group that tends to lose less weight with the new obesity ...

If the proposal is finalized, it could set the stage for a showdown between the pharmaceutical industry and the Trump ...

This may be the first Thanksgiving for millions of Americans who are on GLP-1 agonists like Ozempic, Zepbound or Wegovy.

In the largest study to date on the effects of the drugs on the kidneys, researchers found GLP-1s help the protect the organs ...